ibrutinib
Showing 26 - 50 of 220
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Active, not recruiting
- Prolymphocytic Leukemia
- +2 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell Trial in Whittier (Pirtobrutinib, Ibrutinib)
Recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Pirtobrutinib
- Ibrutinib
-
Whittier, CaliforniaInnovative Clinical Research Institute
Aug 8, 2022
Mantle-Cell Lymphoma Trial in United States (Ixazomib, Ibrutinib)
Active, not recruiting
- Mantle-Cell Lymphoma
- Ixazomib
- Ibrutinib
-
Atlanta, Georgia
- +13 more
Nov 17, 2022
Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)
Active, not recruiting
- Waldenstrom Macroglobulinemia
- Ibrutinib
- Rituximab
-
Chiba, Japan
- +8 more
Jan 27, 2023
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in
Recruiting
- Ann Arbor Stage II Follicular Lymphoma
- +5 more
- Ibrutinib
- +2 more
-
Fresno, California
- +2 more
Jan 24, 2023
Colon Cancer, Colorectal Cancer, Colorectal Carcinoma Trial in Tampa (Pembrolizumab, Ibrutinib)
Completed
- Colon Cancer
- +3 more
- Pembrolizumab
- Ibrutinib
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2022
Leukemia, Lymphocytic, Chronic Trial in Germany (ibrutinib, obinutuzumab, venetoclax)
Completed
- Leukemia, Lymphocytic, Chronic
- ibrutinib
- +2 more
-
Dresden, Germany
- +10 more
Jan 13, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin Trial in Worldwide (JNJ-67856633, Ibrutinib)
Active, not recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Non-Hodgkin
- JNJ-67856633
- Ibrutinib
-
Copenhagen, Denmark
- +9 more
Jan 27, 2023
Waldenstrom Macroglobulinemia, MYD88 Gene Mutation Trial in Boston (IBRUTINIB, Venetoclax)
Active, not recruiting
- Waldenstrom Macroglobulinemia
- MYD88 Gene Mutation
- IBRUTINIB
- Venetoclax
-
Boston, Massachusetts
- +1 more
Apr 1, 2022
Refractory Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Washington, Hackensack, Seattle (Ibrutinib, Venetoclax)
Recruiting
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
- Ibrutinib
- Venetoclax
-
Washington, District of Columbia
- +2 more
Jul 6, 2022
Waldenstrom Macroglobulinemia Trial in Austria, Germany, Greece (Carfilzomib + Ibrutinib, Ibrutinib)
Recruiting
- Waldenstrom Macroglobulinemia
- Carfilzomib + Ibrutinib
- Ibrutinib
-
Salzburg, Austria
- +16 more
Mar 11, 2022
Relapsed/Refractory Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Leukemia Trial in Switzerland (Ibrutinib,
Active, not recruiting
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- +2 more
- Ibrutinib
- Venetoclax
-
Aarau, Switzerland
- +10 more
Mar 10, 2022
Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Not yet recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +5 more
- Ibrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
Chronic Lymphocytic Leukemia (CLL) Trial (Venetoclax, Rituximab, Ibrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Venetoclax
- +2 more
- (no location specified)
Apr 2, 2022
Chronic Lymphocytic Leukemia Trial in Boston, Hackensack, New York (Ublituximab, Umbralisib, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ublituximab
- +4 more
-
Boston, Massachusetts
- +2 more
Aug 19, 2022
Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)
Terminated
- Small Lymphocytic Leukemia (SLL)
- Chronic Lymphocytic Leukemia (CLL)
- Duvelisib
- Ibrutinib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 15, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)
Recruiting
- Lymphoma
- +3 more
- obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Tumor, Chronic Lymphocytic Leukemia Trial in Rochester (Ibrutinib,
Withdrawn
- Asymptomatic COVID-19 Infection Laboratory-Confirmed
- +8 more
- Ibrutinib
- Quality-of-Life Assessment
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 2, 2022
Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)
Active, not recruiting
- Relapsed Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- ABT-199
- +2 more
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome Trial in United
Completed
- Chronic Myelomonocytic Leukemia
- +4 more
- Azacitidine
- Ibrutinib
-
Los Angeles, California
- +4 more
Oct 5, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the NHLBI (Ibrutinib, Fludarabine)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Ibrutinib
- Fludarabine
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Mar 1, 2022
Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)
Recruiting
- Chronic Lymphocytic Leukemia
- Daratumumab
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 24, 2022
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Stage I Chronic Lymphocytic Leukemia
- +3 more
- Ibrutinib
- Laboratory Biomarker Analysis
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 24, 2022